Compare CTRI & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTRI | HCM |
|---|---|---|
| Founded | 1909 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | 2024 | 2015 |
| Metric | CTRI | HCM |
|---|---|---|
| Price | $21.53 | $13.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $28.17 | $20.59 |
| AVG Volume (30 Days) | ★ 1.6M | 39.6K |
| Earning Date | 11-05-2026 | 07-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 412.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,982,781,000.00 | N/A |
| Revenue This Year | $23.78 | $14.24 |
| Revenue Next Year | $12.91 | $11.52 |
| P/E Ratio | ★ N/A | $5.49 |
| Revenue Growth | ★ 13.10 | N/A |
| 52 Week Low | $18.60 | $9.77 |
| 52 Week High | $42.99 | $16.33 |
| Indicator | CTRI | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 60.84 | 46.18 |
| Support Level | $21.35 | $13.00 |
| Resistance Level | $28.61 | $15.10 |
| Average True Range (ATR) | 0.84 | 0.37 |
| MACD | 0.17 | -0.11 |
| Stochastic Oscillator | 87.80 | 27.20 |
Centuri Holdings Inc is a pure-play North American utility infrastructure services company that partners with regulated utilities to maintain, upgrade and expand the energy network that powers millions of homes and businesses. Its service offerings consist of the modernization of utility infrastructure through the maintenance, retrofitting and installation of electric and natural gas distribution networks to meet current and future demands while also preparing systems for the transition to clean energy sources. Its reportable segments are: (i) U.S. Gas Utility Services (U.S. Gas); (ii) Canadian Utility Services (Canadian Operations); (iii) Union Electric Utility Services (Union Electric); and (iv) Non-Union Electric Utility Services (Non-Union Electric).
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.